Evaluation of Lateral Temporal Bone Resection in Locally Advanced Tumours of the Parotid Gland
- 26 Downloads
This study evaluated the effects of lateral temporal bone resection (LTBR) on local tumour control in patients with locally advanced parotid gland tumours. The medical records of seven patients treated with radical parotidectomy combined with LTBR for locally advanced primary parotid tumour at the Otolaryngology Department of Dokuz Eylul University between January 1995 and December 2016 were retrospectively evaluated. Demographic variables, tumour characteristics, treatment properties, postoperative complications, follow-up durations and local, regional and distant recurrences were analysed. Before referral to our clinic, four patients had de novo primary parotid tumours, and three patients had a recurrence of primary parotid tumours. The histopathologic diagnoses were squamous cell carcinoma in two patients, and adenosquamous carcinoma, malignant myoepithelial carcinoma, adenocarcinoma, adenoid cystic carcinoma and spindle cell sarcoma in the other patients. During the follow-up period, one patient died due to postoperative pulmonary embolism in the first month, and four patients died due to distant metastasis without local or regional recurrences. LTBR combined with radical parotidectomy in locally advanced primary malignant parotid gland tumours is a feasible surgical technique for local tumour control. However, the most common cause of death in these cases is distant metastases, despite appropriate resection.
KeywordsLateral temporal bone resection Parotid neoplasms Salivary gland neoplasms Squamous cell carcinoma Temporal bone
There is not any funding organisations to be disclosed for the present study.
Compliance with Ethical Standards
Conflict of interest
The authors have no funding, financial relationships or conflict of interest to disclose.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 4.Kane WJ, McCaffrey TV, Olsen KD, Lewis JE (1991) Primary parotid malignancies. A clinical and pathologic review. Arch Otolaryngol Head Neck Surg 117(3):307–315. https://doi.org/10.1001/archotol.1991.01870150075010 CrossRefPubMedGoogle Scholar
- 6.Nagliati M, Bolner A, Vanoni V, Tomio L, Lay G, Murtas R, Deidda MA, Madeddu A, Delmastro E, Verna R, Gabriele P, Amichetti M (2009) Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori 95(4):442–448. https://pdfs.semanticscholar.org/8316/18f829e14183d530b245f43a8ce49cd0e313.pdf CrossRefGoogle Scholar
- 7.Terhaard CHJ, Lubsen H, Rasch CRN, Levendag PC, Kaanders HHÀM, Tjho-Heslinga RE, van Den Ende PLA, Burlage F (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61(1):103–111. https://doi.org/10.1016/j.ijrobp.2004.03.018 CrossRefPubMedGoogle Scholar
- 14.Shao A, Wong DK, McIvor NP, Mylnarek AM, Chaplin JM, Izzard ME, Patel RS, Morton RP (2013) Parotid metastatic disease from cutaneous squamous cell carcinoma: prognostic role of facial nerve sacrifice, lateral temporal bone resection, immune status and P-stage. Head Neck 36(4):545–550. https://doi.org/10.1002/hed.23323 CrossRefPubMedGoogle Scholar
- 16.Parsons H, Lewis JS (1954) Subtotal resection of the temporal bone for cancer of the ear. Cancer 7(5):995–1001. https://doi.org/10.1002/1097-0142(195409)7:5%3C995:AID-CNCR2820070524%3E3.0.CO;2-A CrossRefPubMedGoogle Scholar
- 19.Gaughan RK, Olsen KD, Lewis JE (1992) Primary squamous cell carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 118(8):798–801. https://doi.org/10.1001/archotol.1992.01880080020006 CrossRefPubMedGoogle Scholar
- 22.Cerda T, Sun XS, Vignot S, Marcy PY, Baujat B, Baglin AC, Ali AM, Testelin S, Reyt E, Janot F, Thariat J (2014) A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network). Crit Rev Oncol Hematol 91(2):142–158. https://doi.org/10.1016/j.critrevonc.2014.02.002 CrossRefPubMedGoogle Scholar
- 23.Nutting CM, Rowbottom CG, Cosgrove VP, Henk JM, Dearnaley DP, Robinson MH, Conway J, Webb S (2001) Optimisation of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, three-dimensional conformal, and intensity-modulated techniques. Radiother Oncol 60(2):163–172. https://doi.org/10.1016/S0167-8140(01)00339-5 CrossRefPubMedGoogle Scholar